FDA Proposes 503B Bulk-Compounding Exclusions for Semaglutide, Tirzepatide & Liraglutide

FDA's May 2026 notice proposed not including semaglutide, tirzepatide and liraglutide on the 503B clinical-need bulks list. The comment period closed July 30.

That notice is not a final determination, does not eliminate the separate drug-shortage route and does not decide whether an individual 503A prescription meets the law.

May 8, 20268 min read

By GLP-1 Picks, an independent comparison publication. Sources linked below. Our editorial policy.

Summarize this article with

An open folder of blank paper on a wooden desk.

Three different questions sit behind headlines about a compounding ban: whether a substance belongs on the 503B clinical-need list, whether a drug is in shortage, and whether a particular preparation meets all applicable requirements.

The May 1 notice addresses the first.

It was filed April 30 and proposes not including the three substances on that list, rather than removing entries already on it.

The distinction that matters

The clinical-need bulks list and the drug-shortage list are separate routes under Section 503B. A proposal about one is not a blanket ruling on the other, or on patient-specific compounding under Section 503A.

This guide explains the dated notices and decisions below; it does not establish whether FDA has issued a later final determination.

Check the rules before you choose a program

Ask any program which medication you'd get, which pharmacy makes it and who writes the prescription. The FDA alerts page shows what has changed.

Read FDA alerts and compounding updates →

Which compounding pathway does the proposal address?

FDA's notice and statutory background distinguish the clinical-need list from the separate shortage route.

Neither route waives the other conditions that apply to an outsourcing facility.

Which compounding pathway does the proposal address?
PathwayWhat it concernsWhat this notice does not establish
503B clinical-need bulks listWhether an outsourcing facility may use a listed bulk drug substance based on clinical needThe notice proposes not including semaglutide, tirzepatide and liraglutide; it is not itself a final determination
503B drug-shortage routeA separate statutory route involving drugs on FDA's shortage listA clinical-need-list determination does not by itself eliminate this route or guarantee that a hypothetical future preparation would qualify
503A patient-specific compoundingCompounding subject to individual-prescription requirements and all other applicable conditions, including limits on essentially copied drugsThis 503B notice does not certify a particular 503A prescription as compliant

FDA evaluated the nominated substances using its clinical-need framework, including approved products and proposed compounded attributes. Its tentative conclusion was not to include these three substances.

That is more specific than saying FDA approved a permanent ban on every compounded GLP-1 prescription.

What is a 503B outsourcing facility?

A facility elects to register with FDA as an outsourcing facility for sterile compounding and must comply with Section 503B.

FDA's outsourcing-facility explanation says these facilities remain subject to current good manufacturing practice requirements, risk-based FDA inspections, adverse-event reporting and other conditions.

Registration is not a license from FDA to sell any compounded product, and it does not make the resulting drugs FDA-approved.

The notice describes non-patient-specific office stock for healthcare practitioners. That differs from the individual-patient prescription framework under Section 503A, which also has limited anticipatory-compounding conditions.

Neither description is a complete test of a pharmacy's or prescription's compliance.

How is the proposal different from the shortage decisions?

The shortage decisions and post-shortage enforcement policies have their own chronology.

FDA's dated policy log records the determinations and court-related transition periods.

Do not substitute the 2026 comment deadline for those earlier dates.

How is the proposal different from the shortage decisions?
DrugShortage determination in FDA's logPost-shortage transition described by FDA
SemaglutideShortage resolved February 21, 2025The 503A period ended after the April 24, 2025 injunction denial. The 503B period ended May 22, 2025.
TirzepatideInitial resolution October 2, 2024; FDA re-evaluated and issued its December 19, 2024 determinationThe 503A period ended after the March 5, 2025 injunction denial. The 503B period ended March 19, 2025.

Those historical transitions are distinct from the clinical-need-list proposal. A product being advertised today does not prove that the preparation satisfies an available statutory route.

Our post-shortage semaglutide guide and compounded tirzepatide guide explain the related access questions.

What did the August 27 court decisions actually decide?

Two August 27, 2026 Fifth Circuit opinions affirmed the district-court judgments in the challenges to FDA's shortage determinations.

The distinction between their procedural and substantive reasoning matters: an unsuccessful challenge does not mean the court decided every question in FDA's favor.

What did the August 27 court decisions actually decide?
AppealDrug and partiesDisposition
25-10600Tirzepatide; FDA, Outsourcing Facilities Association and Eli Lilly as intervenorAffirmed
25-10758Semaglutide; FDA, Outsourcing Facilities Association and Novo Nordisk as intervenorAffirmed

On notice-and-comment procedure, the panels did not decide whether FDA had made a procedural error.

The tirzepatide opinion found that the challengers had not shown prejudice; the semaglutide opinion treated any such error as harmless. Those holdings should not be described as a merits endorsement of FDA's procedural choice.

Separately, the courts rejected the arbitrary-and-capricious challenges to the shortage determinations on the administrative records before them. That analysis concerned FDA's supply-and-demand judgments.

It was not an approval of compounded products or a ruling on an individual patient's prescription.

Both opinions name Judges Richman, Duncan and Oldham, are per curiam and state that they are not designated for publication.

Read the actual tirzepatide opinion and semaglutide opinion for their holdings.

These August opinions do not establish later mandate, rehearing or Supreme Court docket status.

Why does the notice also name liraglutide?

FDA evaluated liraglutide under the same clinical-need framework as semaglutide and tirzepatide.

The notice's liraglutide assessment sets out that analysis.

As with the other two substances, the assessment concerns the clinical-need list, not elimination of the separate shortage route.

A molecule's shortage-list status and the availability of a particular branded or generic presentation are also different questions. Check the specific product rather than treating liraglutide as a single inventory item.

For product-specific access and continuity-of-care questions, use our Saxenda access and switching guide.

Does the proposal decide what a 503A pharmacy can dispense?

Not by itself. Section 503A has its own conditions.

FDA's April 1, 2026 policy explanation discusses individual-patient prescriptions and restrictions on products that are essentially copies of commercially available drugs.

Where a patient-specific change is relevant, the prescriber must determine and document the significant difference for that patient.

  • •An identified-patient prescription or the applicable limited anticipatory-compounding conditions still matter.
  • •A documented change, allergy, dose preference or lower price alone does not establish that every federal and state requirement is satisfied.
  • •Ingredient eligibility, the essentially-copy restrictions and other applicable conditions require their own analysis. Neither a clinic's marketing nor an on-page comparison is a legal determination.

Ask the prescriber and dispensing pharmacy which route and conditions apply to the exact preparation.

Our compounded-provider safety checks help organize those questions; they do not certify a prescription or batch.

Was the July peptide meeting a different decision?

Yes.

FDA's July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting page concerns substances nominated for the separate 503A bulks list.

Its agenda identifies the following evaluated uses, not a general authorization to sell these peptides.

Was the July peptide meeting a different decision?
Meeting daySubstanceUse in FDA's agenda
July 23BPC-157, free base and acetateUlcerative colitis
July 23KPV, free base and acetateWound healing and inflammatory conditions
July 23TB-500, free base and acetateWound healing
July 23MOTs-C, free base and acetateObesity and osteoporosis
July 24Emideltide / DSIP, free base and acetateOpioid withdrawal, chronic insomnia and narcolepsy
July 24Semax, free base and acetateCerebral ischemia, migraine and trigeminal neuralgia
July 24Epitalon, free base and acetateInsomnia

The committee gives nonbinding recommendations; FDA is not legally bound by them.

An agenda is not a vote record, and a recommendation is not approval of a finished drug, a finding of safety or effectiveness, or proof that a particular compounded preparation meets the law.

The meeting page alone does not establish a later FDA determination.

What does a manufacturing warning tell you about safety?

It tells you what FDA found at the named firm, not the quality of every compounded product.

In its April 15, 2026 warning letter to Hangzhou Yiqi Biotechnology, FDA described failures involving process validation, analytical test methods and stability controls.

The letter also records prior placement on Import Alert 66-40 on January 30, 2026. It does not establish the firm's current border status or identify every medicine that a particular clinic supplies.

FDA's concerns about unapproved GLP-1 drugs are separate from the clinical-need proposal.

FDA cautions that adverse-event reporting is incomplete and that a direct causal link cannot always be determined.

Reports are not a treatment-risk rate, and a single firm's warning is not evidence of contamination in every pharmacy's products.

When did the comment period close, and where can you read the record?

The original deadline was June 30, 2026.

FDA's June 26 extension notice, 91 FR 38719 extended it to July 30, 2026, under Docket FDA-2018-N-3240.

That deadline has passed. The notices and docket are useful for reading the record, not an invitation to file a timely comment under the expired window.

The extension explains that comments would inform FDA's final determination about inclusion on the list. A closed comment period is not itself a final determination. Consult the current agency record for any later action.

What should you check before changing or paying for treatment?

Start with the exact medication and pharmacy, not a headline about compounding. A licensed prescriber addresses treatment suitability; the pharmacy must address the requirements for the preparation it supplies.

Do not start, stop or change treatment based on this article.

  • •Identify the prescribed medicine, formulation, route and dispensing pharmacy.
  • •Ask which applicable compounding conditions the pharmacy relies on. A marketing claim, registration or prescription alone is not a full compliance assessment.
  • •Check the current FDA record for the product and any relevant alerts. Our FDA alerts page provides sourced onward reading.
  • •If a clinician recommends an approved alternative, distinguish the branded product from compounded tablets or injections. Our oral GLP-1 guide separates those formats and approval categories.
  • •Compare the actual first charge, commitment and renewal through the relevant pricing owner. A historical regulatory article should not substitute an old advertised monthly price for your current quote.

This is educational information, not medical or legal advice. The dated notices, policy entries, meeting agenda and court opinions below answer different questions.

None certifies an individual prescription, pharmacy batch or current personal eligibility.

Sources

Medical disclaimer: This article is general information, not medical advice. Talk to a licensed clinician before you start, stop or change any medication. Prices and rules can change after the date we checked them.

Affiliate disclosure: Some links in this article are affiliate links. If you join a program through one, we may earn a commission at no extra cost to you.

Independent Clinical Perspective

What the doctors say

Quotes from named doctors and medical bodies, each linked to where they said it. We did not ask for them, and they do not endorse any provider.

“For more than a million people at high risk of heart attack and stroke, this treatment on the NHS could be life-changing: offering a powerful new way to protect their hearts and improve their health.”
Helen Williams, Consultant pharmacist; National Clinical Director for Cardiovascular Disease Prevention
NHS England
NHS England announcing semaglutide (Wegovy) availability to cut heart attack and stroke risk.
NHS England ↗ · Apr 2026
“So-called 'weight loss drugs' like semaglutide have proven benefits beyond reducing the number on the scales. They are now considered important medicines for preventing deadly heart attacks and strokes. Today's guidance will no doubt help save lives as cardiovascular disease is still one of the country's biggest killers.”
Sonya Babu-Narayan, Consultant cardiologist; Clinical Director, British Heart Foundation
British Heart Foundation
British Heart Foundation reacting to NICE recommending semaglutide for cardiovascular event prevention.
“More options for people with these challenging diseases will be very helpful, particularly if the new oral tablet medicines are priced reasonably.”
Daniel Drucker, MD, endocrinologist, co-discoverer of GLP-1's biological actions; 2025 Breakthrough Prize laureate
University of Toronto / Sinai Health
On head-to-head data for the oral GLP-1 pill orforglipron vs oral semaglutide.

Quotes are general medical commentary about GLP-1 medications, independently sourced and not solicited by GLP-1 Picks. They are not an endorsement of any provider, our provider scores are set solely by our published methodology.

Featured Partners

Affiliate partners we feature. We may earn a commission.

Embody

Embody illustration of a compounded semaglutide injection vial
from $49/mo·Compounded

Collective

Collective provider illustration of compounded semaglutide injection vial
from $59/mo + $199/year membership after 21 days·Compounded

Gala

Current program options·Brand & Compounded

Check the medication, commitment and total price for your selected plan.

Affiliate links, we earn a commission at no extra cost to you. These are featured partners, prioritized by our affiliate economics, not an editorial "best" ranking. Published scores have different evidence limits and do not establish better care. See the program comparison and scoring limitations.